| Supplementary Protection Certificate (SPC) Summary | |||
| SPC No. | 2017/035 | ||
|---|---|---|---|
| Date of filing | 15/08/2017 | ||
| Notification of Application Published | 06/09/2017 | ||
| Status | Rejected | ||
| Notification of Grant Published | |||
| Date of Expiry of SPC | |||
| Applicant |
GEORGETOWN UNIVERSITY 37th and O Streets, N.W. Washington, DC 20057 UNITED STATES OF AMERICA |
||
| Patent Number | 1776957 | ||
| Title of Invention | USE OF HERPES VECTORS FOR TUMOR THERAPY | ||
| Date of Expiry of Patent | 11/08/2018 | ||
| Product Type | Medicinal Product | ||
| Product Identity | Talimogene laherparepvec | ||
| Market Authorisation | Ireland | ||
| Authorisation No | EU/1/15/1064/001 and EU/1/15/1064/002 | ||
| Authorisation Date | 16/12/2015 | ||
| Identity of Product Authorised | Imlygic-talimogene laherparepvec | ||
| Address for Service |
Anne Ryan & Co 2 Crofton Terrace Dun Laoghaire Co. Dublin A96 V6P7 IRELAND |
||
| Renewal Fees | |||
| 17/08/2017 | Request for grant a Supplementary Protection Certificate filed on 15/08/2017, numbered 2017/035. | ||
| 05/05/2021 | Request for grant of Supplementary Protection Certification No. 2017/035 rejected in respect of Article 10(2) of Regulation (EC) No. 469/2009 | ||
| 19/05/2021 | Written statement of grounds issued on 19 May 2021. | ||
| 20/10/2021 | Appeal against decision of the Controller filed in the High Court on 18 August 2021 [Record No. 2021/144Sp] | ||
| 20/10/2021 | Notice of discontinuance of appeal against decision of the Controller filed on 14 October 2021 [2021 No. 144 Sp] | ||